ATHENA-MONO Trial with Bradley J. Monk
In this episode of the IJGC podcast, Editor-in-Ch…
BMJ talk medicine · BMJ Group
September 12, 202243m 9s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Bradley J. Monk to discuss the ATHENA-MONO clinical trial. Prof. Monk is an international thought leader and clinical trialist who has developed and advocated for maintenance treatment in newly diagnosed advanced and recurrent ovarian cancer. ATHENA-MONO represents his fifth positive randomized phase 3 trial studying maintenance treatment and adds confidence to this efficacious and tolerable paradigm changing opportunity for all patients regardless of the molecular genotype (allcomers).
Highlights:
- Maintenance therapy is now the global standard of care in patients with advanced or recurrent epithelial ovarian cancer. This can include a PAPP inhibitor, bevacizumab, or the combination.
- Maintenance treatment is efficacious in all molecular subgroups and is tolerable without an impairment in the quality of life.
- Payers acknowledge the value of maintenance treatment as do consensus guidelines.